Diabetic Retinopathy has proven to be a major breakthrough among diabetic patients by preventing the potential risk of blindness

                                                              Diabetic Retinopathy

Diabetic retinal disease is a condition in which the blood vessels to the retina are damaged. It occurs when the body's production of the vision-making insulin molecule, rhodopsin, is insufficient. People with diabetes have an increased risk of having diabetic retinopathy (diabetic retinal degeneration).

Diabetic retinitis is a visual disorder that can lead to blindness and vision loss in those with diabetes. It occurs when blood vessels in the middle layer of the retina, called the erythrocyte layer, are damaged. Diabetes usually increases the level of uric acid in the blood. The normal balance of this acid is maintained by the kidney, but if the kidneys are unable to remove much sugar (sugar), uric acid will build up in the bloodstream. As a result, there is a condition called diabetic retinopathy.

In addition to the vision impairment that occurs with diabetic retinopathy, people with diabetes also have other problems associated with their eyes such as cataracts and macular edema. They can both be treated using the same techniques. In order for the macula to stay healthy, the retina must be well protected from unnecessary trauma. Surgery, either open ophthalmic laser surgery or laser photodynamic surgery, is often necessary to repair damage to the macula. Both procedures involve the use of lasers to help damage the macula so it may heal.

Typically, diabetic retinopathy only presents itself in people with high blood pressure. The symptoms may not appear until one has developed severe, blind spot vision or if high blood pressure is present for an extended period of time. Either way, once these symptoms start, they are very hard to miss. Open ophthalmic laser treatment for diabetic retinopathy usually takes place in a surgical center. The surgery may involve sutures being placed into the iris so that the surgeon can pull the tear duct out of the eye. If the surgeon does not do this, the result can be an infection in which the eye will need to be irrigated with antibiotics. Recently, in May 2019, Regeneron Pharmaceuticals Inc. received the U.S. Food and Drug Administration (FDA) approval for EYLEA Injection to treat all stages of diabetic radiotherapy and thereby reduce the risk of blindness.